A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Inclusion Criteria:

* Patient has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist
* Patient has life expectancy of greater than 3 months
* Patient is able to swallow capsules

Exclusion Criteria:

* Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug
* Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
* Patient has active CNS metastases and/or carcinomatous meningitis
* Patient has primary central nervous system tumor
* Patient has a history of drug or alcohol abuse
* Patient has Hepatitis B or C
* Patient is HIV positive
* Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug